Accelerating Success

From start-up to standout.

We provide start-ups with a structured and comprehensive toolkit for development, milestone achievement and eventual autonomy. Take a look at a few of the success stories from our growing portfolio of diverse and exciting companies.

Technology:
To develop new medical countermeasure for nerve agent exposure

Web site

To develop new medical countermeasure for nerve agent exposure

Developing novel therapeutics for metabolic disorders.

Source:
Case Western Reserve University, University of Texas Southwestern Medical Center

Technology:
First-in-class therapies for enhancing tissue repair and regeneration

Series A:
$5.9M

Investment Date:
Q3 2017

Web Site

First-in-class therapies for enhancing tissue repair and regeneration

Source:
University of Minnesota

Technology:
Oncology: A new class of therapies to break drug resistance in cancer

Series A:
$7M

Investment Date:
Q4 2016

Web Site

A new class of therapies to break drug resistance in cancer

Source:
MD Anderson Cancer Center

Technology:
Treating neurodegeneration and neuronal injuries through the development of novel therapeutics that can prevent neuronal cell death.

Series A:
$31M

Investment Date:
Q3 2018

Web site

Treating neurodegeneration and neuronal injuries through the development of novel therapeutics that can prevent neuronal cell death.

Source:
The Rockefeller University

Technology:
New generation of natural product derived therapeutics for human disease.

Series A:
$20M

Investment Date:
Q1 2016

Web Site

New generation of natural product derived therapeutics for human disease.

Source:
Weill Cornell Medicine

Technology:
Novel approach to therapeutics for cancer and metabolic diseases.

Series A:
$48M

Investment Date:
Q1 2016

Graduation Date:
Q3 2017

Web site

Novel approach to therapeutics for cancer and metabolic diseases.

Source:
Entepreneur

Technology:
Oncology: Novel immunotherapy approach and targets for mAbs

Series A:
$5.3M

Investment Date:
Q2 2011

Source:
Johns Hopkins, Wistar Institute

Technology:
Oncology, Metabolic, CNS: Small molecule inhibitors of histone acetyl transferases (HAT’s)

Series A:
$4.4M

Investment Date:
Q4 2010

Follow On $:
$5.85M

Source:
University of Washington

Technology:
Antibody platform: Novel method for rapidly developing high affinity mAbs

Series A:
$4.4M

Investment Date:
Q2 2009

Graduation Date:
Q3 2011

Follow On $:
SOLD

Source:
Nanogen, Inc

Technology:
Oncology, Hematopoeitic Disorders: microRNA inhibition platform solving distribution and delivery

Series A:
$3.5M

Investment Date:
Q3 2008

Graduation Date:
Q4 2011

Follow On $:
$9.9M

Source:
California Institute of Tech.

Technology:
Small molecule GPCR Inhibitors: Next generation in-silico drug design platform

Series A:
$4.5M

Investment Date:
Q2 2008

Source:
Washington State University

Technology:
Oncology: Novel target to prevent tumor invasion and metastasis

Series A:
$1.5M

Investment Date:
Q1 2008

Source:
University of Washington

Technology:
Ischemia/Reperfusion: Recombinant protein effective in-vivo at rescuing I/R injury.

Series A:
$4.5M

Investment Date:
Q2 2006

Follow On $:
$2M

Source:
California Institute of Tech.

Technology:
Multiple Indications: Platform for specific improvement of recombinant proteins and mAbs

Series A:
$3.4M

Investment Date:
Q4 2005

Graduation Date:
Q4 2007

Follow On $:
$39M

Source:
Institute for Systems Biology

Technology:
Clinical Diagnostics: Biomarker platform for discovery of blood circulating biomarkers indicative of organ disease

Series A:
$5M

Investment Date:
Q3 2005

Graduation Date:
Q3 2009

Follow On $:
$30.4M

Source:
Entepreneur

Technology:
Oncology, Infectious Disease: Platform for the discovery of novel mAbs against cancers and pathogens

Series A:
$2M

Investment Date:
Q4 2004

Graduation Date:
Q2 2007

Follow On $:
$33.4M

Source:
Entepreneur

Technology:
Autoimmunity/Inflammation: Platform for discovery of new autoimmune and inflammatory targets.

Series A:
$4.8M

Investment Date:
Q2 2004

Graduation Date:
Q2 2006

Follow On $:
$45.1M

Source:
Iowa State University

Technology:
Infectious Disease: Platform for development of vaccines against many pathogens

Series A:
$1.6M

Investment Date:
Q1 2004